PE20120881A1 - Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) como moduladores del receptor de serotonina 5-ht6 - Google Patents
Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) como moduladores del receptor de serotonina 5-ht6Info
- Publication number
- PE20120881A1 PE20120881A1 PE2011001879A PE2011001879A PE20120881A1 PE 20120881 A1 PE20120881 A1 PE 20120881A1 PE 2011001879 A PE2011001879 A PE 2011001879A PE 2011001879 A PE2011001879 A PE 2011001879A PE 20120881 A1 PE20120881 A1 PE 20120881A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- methyl
- bencensulfonamide
- piperazine
- serotonin
- Prior art date
Links
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title abstract 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title abstract 4
- 108091005435 5-HT6 receptors Proteins 0.000 title abstract 2
- 150000004050 homopiperazines Chemical class 0.000 title abstract 2
- 229940076279 serotonin Drugs 0.000 title abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 3
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000022821 personality disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
REFERIDA A UN DERIVADO DE PIPERAZINA U HOMOPIPERAZINA DE FORMULAS (I) O (I'), DONDE X ES UN ENLACE O N-R4; R1 ES H O METILO; R2 ES H O METILO; R3 ES H, ALQUILO C1-C3, FLUOR, ENTRE OTROS; R4 ES H, ALQUILO C1-C4, CICLOALQUILO C3-C4, ENTRE OTROS; R5 ES H, F, Cl, ALQUILO C1-C2, ENTRE OTROS; R6 ES H, F O Cl; n ES 1 O 2. SON SOMPUESTOS PREFERIDOS: CLORHIDRATO DE N-(3-DIFLUOROMETOXI-FENIL)-4-METIL-3-PIPERAZIN-1-IL-BENCENSULFONAMIDA, CLORHIDRATO DE 1-[5-(3-DIFLUOROMETOXI-BENCENSULFONIL)-2-METIL-FENIL]-PIPERAZINA, CLORHIDRATO DE N-(4-DIFLUOROMETOXI-FENIL)-4-METIL-3-PIPERAZIN-1-IL-BENCENSULFONAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS ACTUAN MODULANDO LOS RECEPTORES DE SEROTONINA 5-HT6 Y SON UTILES EN EL TRATAMIENTO DE DISFUNCIONES COGNITIVAS TALES COMO ENFERMEDAD DE ALZHEIMER, TRANSTORNOS DE LA PERSONALIDAD TALES COMO ESQUIZOFRENIA, TRANSTORNOS DE ALIMENTACION TALES COMO ANOREXIA, BULIMIA, ENTRE OTRAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17405409P | 2009-04-30 | 2009-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120881A1 true PE20120881A1 (es) | 2012-08-24 |
Family
ID=42236832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001879A PE20120881A1 (es) | 2009-04-30 | 2010-04-29 | Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) como moduladores del receptor de serotonina 5-ht6 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8076326B2 (es) |
| EP (1) | EP2432769B1 (es) |
| JP (1) | JP5718898B2 (es) |
| KR (1) | KR20120016639A (es) |
| CN (1) | CN102459197B (es) |
| AR (1) | AR076507A1 (es) |
| AU (1) | AU2010243585B2 (es) |
| BR (1) | BRPI1011875A2 (es) |
| CA (1) | CA2759482A1 (es) |
| CL (1) | CL2011002653A1 (es) |
| CO (1) | CO6450637A2 (es) |
| CR (1) | CR20110604A (es) |
| DO (1) | DOP2011000326A (es) |
| EC (1) | ECSP11011468A (es) |
| ES (1) | ES2536779T3 (es) |
| IL (1) | IL215642A (es) |
| MX (1) | MX2011011520A (es) |
| NZ (1) | NZ595698A (es) |
| PE (1) | PE20120881A1 (es) |
| RU (1) | RU2535200C2 (es) |
| SG (1) | SG175187A1 (es) |
| TW (1) | TWI465438B (es) |
| UA (1) | UA107080C2 (es) |
| UY (1) | UY32604A (es) |
| WO (1) | WO2010125134A1 (es) |
| ZA (1) | ZA201107569B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009147190A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
| EP2280705B1 (en) | 2008-06-05 | 2014-10-08 | Glaxo Group Limited | Novel compounds |
| ES2445199T3 (es) | 2008-06-05 | 2014-02-28 | Glaxo Group Limited | Derivados de benzpirazol como inhibidores de PI3-quinasas |
| US8524751B2 (en) | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
| ES2876933T3 (es) | 2009-04-30 | 2021-11-15 | Glaxo Group Ltd | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas |
| US8343959B2 (en) * | 2009-04-30 | 2013-01-01 | Abbott Gmbh & Co. Kg | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| WO2012059432A1 (en) * | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor |
| US20140120036A1 (en) * | 2012-01-06 | 2014-05-01 | Abbvie Inc. | Radiolabeled 5-ht6 ligands |
| EP2928866A1 (en) * | 2012-12-10 | 2015-10-14 | F. Hoffmann-La Roche AG | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS |
| JP2016510781A (ja) * | 2013-03-15 | 2016-04-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ＲＯＲｃモジュレーターとしてのアリールスルファミド及びスルファミン酸誘導体 |
| US9663498B2 (en) | 2013-12-20 | 2017-05-30 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
| EP3134392B1 (en) * | 2014-04-19 | 2019-01-02 | Sunshine Lake Pharma Co., Ltd. | Sulfonamide derivatives and pharmaceutical applications thereof |
| EP4419105A4 (en) * | 2021-10-20 | 2025-12-24 | Yousef Najajreh | ALLOSTERIC INHIBITOR COMPOUNDS TO OVERCOME CANCER RESISTANCE |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| HUP0003073A3 (en) * | 1997-07-11 | 2002-10-28 | Smithkline Beecham Plc | Benzenesulfonamide derivatives, process for producing them and their use as medicines |
| GB9818914D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| GB9818916D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| SE0002739D0 (sv) | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New use |
| EP1406884A1 (en) | 2001-05-11 | 2004-04-14 | Biovitrum Ab | Arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders |
| IL158590A0 (en) * | 2001-06-11 | 2004-05-12 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
| NZ530742A (en) * | 2001-08-10 | 2007-07-27 | Hoffmann La Roche | Arylsulfonyl derivatives with 5-HT6 receptor affinity |
| CA2476350C (en) * | 2002-02-22 | 2011-04-05 | Pharmacia & Upjohn Company | Pyridyl sulfone derivatives as 5-ht receptor antagonists |
| GB0305575D0 (en) | 2003-03-11 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
| AU2005266448A1 (en) | 2004-07-28 | 2006-02-02 | Glaxo Group Limited | Piperazine derivatives useful for the treatment of gastrointestinal disorders |
| GB0419192D0 (en) * | 2004-08-27 | 2004-09-29 | Merck Sharp & Dohme | Therapeutic agents |
| WO2007108742A1 (en) * | 2006-03-17 | 2007-09-27 | Astrazeneca Ab | Novel tetralins as 5-ht6 modulators |
| PE20080191A1 (es) * | 2006-04-19 | 2008-03-10 | Abbott Gmbh & Co Kg | Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6 |
| WO2008087123A2 (en) | 2007-01-16 | 2008-07-24 | Solvay Pharmaceuticals B.V. | Use of 5-ht6 antagonists to prevent relapse into addiction |
-
2010
- 2010-04-29 KR KR1020117028393A patent/KR20120016639A/ko not_active Ceased
- 2010-04-29 BR BRPI1011875A patent/BRPI1011875A2/pt not_active IP Right Cessation
- 2010-04-29 PE PE2011001879A patent/PE20120881A1/es not_active Application Discontinuation
- 2010-04-29 WO PCT/EP2010/055789 patent/WO2010125134A1/en not_active Ceased
- 2010-04-29 JP JP2012507761A patent/JP5718898B2/ja not_active Expired - Fee Related
- 2010-04-29 MX MX2011011520A patent/MX2011011520A/es active IP Right Grant
- 2010-04-29 UA UAA201114123A patent/UA107080C2/ru unknown
- 2010-04-29 SG SG2011074325A patent/SG175187A1/en unknown
- 2010-04-29 CA CA2759482A patent/CA2759482A1/en not_active Abandoned
- 2010-04-29 RU RU2011148583/04A patent/RU2535200C2/ru not_active IP Right Cessation
- 2010-04-29 CN CN201080030335.8A patent/CN102459197B/zh not_active Expired - Fee Related
- 2010-04-29 EP EP10719748.5A patent/EP2432769B1/en active Active
- 2010-04-29 NZ NZ595698A patent/NZ595698A/en not_active IP Right Cessation
- 2010-04-29 AU AU2010243585A patent/AU2010243585B2/en not_active Ceased
- 2010-04-29 ES ES10719748.5T patent/ES2536779T3/es active Active
- 2010-04-30 TW TW099113996A patent/TWI465438B/zh not_active IP Right Cessation
- 2010-04-30 US US12/770,837 patent/US8076326B2/en not_active Expired - Fee Related
- 2010-04-30 UY UY0001032604A patent/UY32604A/es not_active Application Discontinuation
- 2010-04-30 AR ARP100101465A patent/AR076507A1/es not_active Application Discontinuation
-
2011
- 2011-10-09 IL IL215642A patent/IL215642A/en not_active IP Right Cessation
- 2011-10-14 ZA ZA2011/07569A patent/ZA201107569B/en unknown
- 2011-10-25 CL CL2011002653A patent/CL2011002653A1/es unknown
- 2011-10-25 DO DO2011000326A patent/DOP2011000326A/es unknown
- 2011-11-03 CO CO11149288A patent/CO6450637A2/es active IP Right Grant
- 2011-11-15 CR CR20110604A patent/CR20110604A/es unknown
- 2011-11-21 EC EC2011011468A patent/ECSP11011468A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120881A1 (es) | Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) como moduladores del receptor de serotonina 5-ht6 | |
| AR076460A1 (es) | Antagonistas del receptor cxcr3 | |
| ECSP066976A (es) | 4-fenilamino-quinazolin-6-il-amidas | |
| PE20090890A1 (es) | Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c | |
| PE20090057A1 (es) | Compuestos y composiciones como moduladores de la actividad gpr119 | |
| PE20121613A1 (es) | Derivados de quinolina amida como moduladores alostericos positivos de receptores m1 | |
| PE20190913A1 (es) | Derivados aromaticos de sulfonamida | |
| PE20080997A1 (es) | Compuestos n-fenilmetil-5-oxo-prolina-2-amida como moduladores de receptores p2x7 | |
| PE20040960A1 (es) | Derivados de piperazina acilados como agonistas del receptor de melanocortina-4 | |
| PE20070115A1 (es) | Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas | |
| PE20091734A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| PE20070528A1 (es) | Compuestos heterociclicos como ligandos del receptor vaniloide del subtipo 1 | |
| PE20071254A1 (es) | Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion | |
| PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
| PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
| PE20060487A1 (es) | Derivados de 2-carbamida-4-feniltiazol como moduladores de la actividad de quimioquinas | |
| CL2007000396A1 (es) | Compuestos derivados de benzoil-piperidina, moduladores del receptor 5ht2/d3; composicion farmaceutica que los comprende;y su uso en el tratamiento y/o prevencion de patologias delsnc, tales como psicosis, esquizofrenia, depresion, ansiedad,adiccion a drogas y problemas cognitivos. | |
| PE20071245A1 (es) | COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs) | |
| PE20110703A1 (es) | Acidos naftilaceticos | |
| PE20090655A1 (es) | Derivados de 2-aza-biciclo[2.2.2]octano para prevencion o tratamiento de psicosis | |
| PE20090622A1 (es) | Nuevos derivados de bencimidazol sustituido | |
| PE20120063A1 (es) | Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3 | |
| PE20091102A1 (es) | Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |